From: The economic impact of sight loss and blindness in the UK adult population
 | England | Wales | Scotland | Northern Ireland | UK |
---|---|---|---|---|---|
Hospital recurrent expenditure | 588.9, 23.9% | 44.7, 29.6% | 85.9, 29.4% | 15.3, 19.1% | 734.9, 24.6% |
Non-admitted expenditure | 673.8, 27.3% | 33.7, 22.3% | 47.3, 16.2% | 16.3, 20.3% | 771.1, 25.8% |
 Prescribing expenditure | 137.9, 5.6% | 9.0, 6.0% | 11.8, 4.0% | 3.9, 4.9% | 162.6, 5.4% |
 Ranibizumab (Lucentis)a | 184.0, 7.5% | 11.6, 7.7% | 17.5, 6.0% | 5.2, 6.5% | 218.3, 7.3% |
General ophthalmic services (GOS) | 481.1, 19.5% | 32.3, 21.4% | 80.9, 27.7% | 20.2, 25.2% | 614.6, 20.6% |
Expenditure associated with injurious falls | 19.9, 0.8% | 1.0, 0.7% | 2.0, 0.7% | 0.6, 0.7% | 23.4, 0.8% |
 | (16.2, 0.7% - 23.7, 1.0%) | (0.8, 0.5% - 1.2, 0.8%) | (1.6, 0.5% - 2.4, 0.8%) | (0.5, 0.6% - 0.7, 0.9%) | (19.1, 0.6% - 28.0, 0.9%) |
Research and development | 14.1, 0.6% | 0.5, 0.3% | 2.1, 0.7% | 0.3, 0.4% | 17.0, 0.6% |
Residential care and community care services | 220.8, 9.0% | 13.2, 8.7% | 31.7, 10.9% | 11.0, 13.7% | 276.8, 9.3% |
Capital and administration | 145.7, 5.9% | 5.1, 3.4% | 12.8, 4.4% | 7.1, 8.9% | 170.7, 5.7% |
Total | 2466.1 | 151.1 | 292.1 | 80.1 | 2989.3 |
 | (2462.4–2469.9) | (150.9–151.3) | (291.7–292.4) | (80.0–80.2) | (2985.0–2993.9) |